Lung Cancer Detection by Measuring Monocyte Activity

Lung Cancer Clinical Trial

— EDLC  

Official title:

Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02090166
• Other study ID #: CMC-13-0105-CTIL
• Status: Not yet recruiting
• Phase: N/A
• First received: March 10, 2014
• Last updated: March 16, 2014
• Start date: April 2014
• Est. completion date: January 2021

Study information

• Verified date: March 2014
• Source: Carmel Medical Center
• Contact: Yochai Adir, MD
• Phone: +972-4-8250517
• Email: yochaiad[@]clalit.org.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Purpose: To evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The study population will include a total of 950 participants, patients with lung cancer before any treatment, and healthy and COPD patients as a control group.

Description:

The purpose of the study is to evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations.

Study Design Prospective, three groups, open, comparative, controlled study. No. of Sites One Study Population Man and Women aged 18 - 90 years old. No. of Subjects A total of 950 completed, evaluated subjects will be enrolled in this study.

The groups sample size is as follows:

Group 1 - 75 subjects Group 2 - 75 subjects Group 3 - 150 subjects Group 4 - 650 subjects

Primary End Point 1. Positive and negative diagnosis (scored 0/1 dichotomously) in accordance with clinical data collected

Data Analysis and Statistics Multiple MA profiles including a huge number of MA rates values are obtained for each subject. In order to develop a dynamic clinical analysis that is updated with every new subject, and to extract patterns from this large data base, The research team designed computer programming using Data Mining tools, which combine methods from statistics and artificial intelligence with database management.

Blood test will be perform from each subject. The blood sample in eah subject will be compare to his status : healthy non smoker, healthy smoker, COPD or diagnosed with lung cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 950
• Est. completion date: January 2021
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria

1. Subject signed the informed consent.

2. Subject is between 18 to 90 years old.

3. Lung cancer diagnosis before any treatment

Exclusion Criteria

1. Lung cancer patients

2. Subject has been previously treated for any type of malignant or benign tumor (for example: colon or uterus polyps removal).

3. Subject has active infection or inflammation determined clinically at screening.

4. Subject is currently treated with concomitant medication related directly or can affect the immune system.

5. Subject lactating or undergoing fertility treatment.

6. Subject has impaired judgment.

7. Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.

8. Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation.

9. Known hypersensitivity and/or allergy

10. Drug or alcohol abuse (by history).

11. Subject is participating in any other clinical trial, drug or device study within 30 days prior sample collection

12. Relatives of the study investigators or employees of the study investigators are not allowed to participate in the study

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• Blood test
a blood test will be taken from each patient

Locations

Country	Name	City	State
Israel	Carmel Medical Center	Haifa

Sponsors (2)

Lead Sponsor	Collaborator
Carmel Medical Center	Tel Aviv University

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive and negative diagnosis (scored 0/1 dichotomously) of lung cancer		1 year	No